Kouros Owzar
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Training Program in Bioinformatics at the Intersection of Cancer Immunology and Microbiome
Open Date: 2020-07-01
Close Date: 2026-06-30
Grant: Close
Breast Pre-Cancer Atlas Center
Open Date: 2018-09-21
Close Date: 2024-08-31
Grant: Close
A hands-on, integrative next-generation sequencing course: design, experiment, and analysis
Open Date: 2016-09-22
Close Date: 2019-06-30
Grant: Close
Statistical Methods for Cancer Clinical Trials
Open Date: 2010-04-01
Close Date: 2020-03-31
Grant: Close
Centers for Medical Countermeasures Against Radiation
Open Date: 2005-08-31
Close Date: 2026-07-31
Articles (22)
Year:
2026
Ductal carcinoma in situ (DCIS) is a risk factor for subsequent invasive breast cancer (IBC). To identify events in DCIS that lead to invasive cancer, we performed single-cell RNA sequencing on DCIS lesions and matched normal breast tissue. Inferred copy-number variation was used to identify neoplastic epithelial cells from clinical specimens, which contained a mixture of DCIS and normal ducts. Phylogenetic analysis demonstrated intratumoral clonal heterogeneity that was associated with significant gene expression differences. Classification of epithelial cells into mammary cell states revealed that subclones contained a mixture of cell states, suggesting an ongoing pattern of differentiation after neoplastic transformation. Cell state proportions were significantly different based on estrogen receptor expression, with estrogen receptor–negative DCIS more closely resembling the distribution in the normal breast, particularly with respect to cells with basal characteristics. Specific alterations in cell state proportions were associated with progression to invasive cancer in a cohort of DCIS with longitudinal outcome. Ongoing transcription of key basement membrane (BM) genes occurred in specific subsets of epithelial cell states, including basal/myoepithelial, which are diminished in DCIS. In the transition to IBC, the BM protein laminin, but not COL4, was altered in DCIS adjacent to invasion. Loss of COL4, but not laminin, in an in vitro DCIS model led to an invasive phenotype. These findings suggest that the process of invasion is a loss-of-function event due to an imbalance in critical cell populations essential for BM integrity rather than a gain of an invasive phenotype by neoplastic cells. Significance: Single-cell analyses reveal ductal carcinoma in situ comprises multiple genetic clones with significant phenotypic diversity and link alterations in epithelial cell states and basement membrane integrity with invasive breast cancer progression.
Year:
2025
Background: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants. Methods: The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across eight timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index, fasting status, and sampling factors. Results: ICC was calculated to determine the reliability of each biomarker. Hepatocyte growth factor was the most stable marker (ICC = 0.973), while platelet-derived growth factor (PDGF)-BB was the most variable marker (ICC = 0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGFβ1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL6 (P = 0.0114). Higher body mass index was associated with higher levels of IL6 (P = 0.0003) and VEGF-R3 (P = 0.0045). Conclusions: Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay. Impact: These data further support the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.
Year:
2025
Year:
2025
Year:
2025
Background Melanoma brain metastases (MBM) have a unique molecular profile compared to extracranial metastases (ECM). Description of the biological features and clinical outcomes of MBM will facilitate the design of rational therapies. Methods We examined the mutational landscape and gene expression profiles of MBM (74 patients) and ECM (34 patients) in paired patient samples from a previously published dataset with whole-exome sequencing (WES) and RNA sequencing (RNAseq) data from MD Anderson Cancer Center (MDACC). We also present findings from MBM from a new cohort of 14 patients from Duke University to strengthen investigation of somatic mutations and gene expression profiles. Gene Set Enrichment Analysis (GSEA) was used to compare paired MBM versus lymph node (LN) metastases and skin metastases. Relative immune cell abundance was inferred using deconvolution methods. Survival outcomes from craniotomy and associations with biological features, BRAF mutation status, and PTEN expression were assessed. Results GSEA found that autophagy signaling pathways are enriched in MBM versus LN and skin metastases. BRAF was the most frequently mutated clinically relevant gene in MBM and ECM, with NRAS and PTEN also frequently altered in MBM. The most strongly upregulated genes in autophagy pathways were glial fibrillary acidic protein ( GFAP ) and hemoglobin beta ( HBB ). An increased proportion of immune-suppressive M2 compared to tumor-suppressive M1 macrophages in MBM and ECM was identified. There was not sufficient evidence for an association between BRAF V600 mutation status or expression and overall survival (OS) from craniotomy. Conclusions The mutational landscape and gene expression of MBM from the Duke cohort resembled those previously reported in the MDACC cohort. Upregulation of autophagy pathways was observed in patient-matched MBM versus LN and skin metastases due to upregulation of two genes, GFAP and HBB . In MBM, higher M2:M1 ratio may contribute to a therapeutically relevant immune-suppressive tumor microenvironment (TME).
Year:
2025
Congenital cytomegalovirus (cCMV) is the leading infectious cause of birth defects worldwide, yet immune determinants of protection to inform design of a maternal vaccine remain elusive. Here, we characterized the outcome of primary rhesus CMV (RhCMV) infection during pregnancy in an immune competent nonhuman primate (NHP) model. RhCMV DNA was detected in amniotic fluid and/or fetal tissues in six of 12 (50% placental transmission) CMV-naive rhesus macaque dams inoculated intravenously with RhCMV in early second trimester gestation. Widespread tissue dissemination dominated by one of two inoculated RhCMV strains was present in one fetus (8.3% cCMV disease). Placental RhCMV transmission was associated with elevated fetal and maternal plasma TNF-alpha and reduced maternal brain-derived neurotrophic factor and IL-10 levels. CMV exposure during pregnancy had a broad impact on the placenta and fetus even in the absence of congenital infection as evidenced by RhCMV infection at the maternal-fetal interface in all 12 dams, along with significantly reduced placental efficiency and fetal growth metrics compared to gestation-matched control pregnancies. This NHP model recapitulates key aspects of human cCMV and provides new insight into barriers and biomarkers of successful vertical transmission. One sentence summary: The nonhuman primate model mirrors the epidemiology of human congenital CMV (cCMV) after primary infection and reveals its transmission bottlenecks.
Year:
2025
Year:
2025
Background Brain metastases (BrM) arising from breast cancer (BC) are an increasing consequence of advanced disease, with up to half of patients with metastatic HER2 + or triple negative BC experiencing central nervous system (CNS) recurrence. The genomic alterations driving CNS recurrence, along with contributions of the immune microenvironment, particularly by intrinsic subtype, remain unclear. Methods We characterized the genomic and immune landscape of BCBrM from a cohort of 42 patients by sequencing whole-exome DNA (WES) and total RNA libraries from frozen and FFPE BrM and FFPE extracranial tumors (ECT). Analyses included PAM50 intrinsic subtypes, somatic mutations, copy number variations (CNV), pathway alterations, immune cell type deconvolution, and associations with clinical outcomes Results Intrinsic subtype calls were concordant for the majority of BrM-ECT pairs (60%). Across all BrM and ECT samples, the most common somatic gene mutation was TP53 (64%, 30/47). For patients with matched FFPE BrM-FFPE ECT, alterations tended to be conserved across tissue type, although differential somatic mutations and CNV in specific genes were observed. Several genomic pathways were differentially expressed between patient-matched BrM-ECT; MYC targets, DNA damage repair, cholesterol homeostasis, and oxidative phosphorylation were higher in BrM, while immune-related pathways were lower in BrM. Deconvolution of immune populations between BrM-ECT demonstrated activated dendritic cell populations were higher in BrM compared to ECT. Increased expression of several oncogenic preselected pathways in BrM were associated with inferior survival, including DNA damage repair, inflammatory response, and oxidative phosphorylation Conclusions Collectively, this study illustrates that while some genomic alterations are shared between BrM and ECT, there are also unique aspects of BrM including somatic mutations, CNV, pathway alterations, and immune landscape. A deeper understanding of differences inherent to BrM will contribute to the development of BrM-tailored therapeutic strategies. Additional analyses are warranted in larger cohorts, particularly with additional matched BrM-ECT.
Year:
2025
Background and Significance: Current therapies for steroid-refractory chronic graft versus host disease (SR-cGVHD) feature limited rates of complete response (CR). The current standard of care for initial treatment is ruxolitinib. While ruxolitinib primarily addresses donor derived T-cells, preclinical studies have demonstrated the role of pathogenic B-Cell Receptor (BCR)-activated B cells in promoting inflammatory cytokine production and driving cGVHD. In murine models, inhibition of the BCR-signaling protein, spleen tyrosine kinase (Syk), has been shown to improve manifestations of pulmonary cGVHD. Fostamatinib is a Syk inhibitor approved for the treatment of chronic ITP. A phase I clinical trial of fostamatinib monotherapy in 14 patients with SR-cGVHD demonstrated an overall response rate of 77% (31% CR), with a median duration of response of 19.3 months. Data on combinatorial strategies in cGVHD are currently limited. We hypothesize that targeting both pathologic B cells in addition to alloreactive T cells may have a synergistic effect in enhancing responses in SR-cGVHD. Study Design and Methods: This is an open-label phase I clinical trial (NCT06233110) evaluating the combination of fostamatinib and ruxolitinib for the treatment of cGVHD with a suboptimal response to corticosteroids. This trial is currently actively enrolling at Duke University (Durham, NC, USA). The primary objective is to identify a minimum safe and biologically effective dose of fostamatinib when combined with standard of care ruxolitinib for SR-cGVHD. Secondary and exploratory objectives include evaluating the efficacy of treatment, assessing the impact on quality of life through the Lee Symptom Scale, and studying changes in pathogenic B cell hyperresponsiveness before and after treatment with ruxolitinib and fostamatinib. The clinical trial features two phases: an initial dose escalation phase and a subsequent safety expansion phase. The dose escalation phase will follow a modified 3+3 design, evaluating fostamatinib at doses of 100mg daily, 150mg daily, and 100mg twice daily, in combination with ruxolitinib 10mg twice daily. Each dose level may be backfilled to a total of 6 patients for pharmacokinetic (PK) and pharmacodynamic (PD) assessments. At the end of the dose escalation phase, two candidates for the biologically optimal fostamatinib dose will be selected based on PK, PD, efficacy, and safety data. The safety expansion phase will randomize additional patients to receive one of the two candidate fostamatinib doses together with standard dose ruxolitinib, enrolling up to 12 patients per arm. In the absence of dose-limiting toxicity and progression of cGVHD, fostamatinib is continued for at least six months. In patients who achieve a CR, fostamatinib will be weaned at 6 months. Duration of ruxolitinib as a standard of care therapy is per investigator discretion. Eligibility: Adults who have undergone an allogeneic hematopoietic cell transplantation and have active cGVHD with a suboptimal response to corticosteroids are eligible. Suboptimal response is defined as (1) cGVHD progression after prednisone 1 mg/kg/d x 1 week, (2) cGVHD persistence despite prednisone 0.5 mg/kg/d x 4 weeks, (3) increase in prednisone dose to 0.25 mg/kg/d or higher after 1 unsuccessful taper attempt, (4) recurrence of cGVHD after attaining a CR with steroids, or (5) progression of cGVHD after attaining a partial response with steroids. Additional major inclusion criteria include adequate bone marrow function, adequate organ function, and Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Major exclusion criteria include prior treatment with a SYK inhibitor for cGVHD, active or relapsed malignancy, SR-cGVHD occurring after a non-scheduled donor lymphocyte infusion, active uncontrolled infections, uncontrolled hypertension > 160/100, and pregnancy. Of note, prior treatment with ruxolitinib for cGVHD for longer than 3 weeks is not permitted at this time,
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (22)
Aashrith Saraswathibhatla
Assistant Professor
University of Minnesota
Joshua Granek
Assistant Professor at Duke University
Duke University
John Christopher Brady
Duke University
Robert B. West
Stanford University School of Medicine
Carey Anders
Assistant Director of Clinical Research
Duke University
Jichun Xie
Associate Professor
Duke University
Graham A. Colditz
Chief, Division of Public Health Sciences
Washington University in St. Louis
Chunfang zhu
Stanford University School of Medicine
Kathleen Houlahan
McMaster University
Cliburn Chan
Duke University
Xiaodi Qin
Duke University
E. Shelley Hwang
Duke University
Liuyang Wang
Research Associate Professor
Duke University
Christina Curtis
Professor of Medicine & Genetics
Stanford University
Rachel Factor
Associate Professor
Duke University Health System
Siri Strand
Assistant professor
Aarhus Universitetshospital
Sanghee Hong
Duke University
Ovijit Chaudhuri
Associate Professor
Stanford University
Daniel Hertz
University of Michigan
Andrew Nixon
Duke University Medical Center
Shu Jiang
Associate Professor
Washington University in Saint Louis School of Medicine
S. Percy Ivy
Associate Chief
National Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.